Syndax ⁠scores FDA approval for Revuforj after it disappointed in another acute leukemia indication Shorla, which is based in the U.S. and Ireland, estimated that this year in the U.S. more than ...

FDA approves BridgeBio's Attruby for ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market Attruby is ...

The drug company had been searching for a new chief scientific officer since July with Dolsten leaving after 15 years at the company, having joined in 2009 as part of Pfizer’s acquisition of Wyeth.

On Friday, the FDA approved BridgeBio Pharma ... Also Read: BridgeBio Pharma’s Acoramidis Shows Competitive Edge Against Pfizer’s Tafamidisa In Lucrative But Competitive ATTR-CM Market ...

The drug, marketed under the name Attruby, was proven under testing to postpone the hospitalizations for people living with the disease. STORY HIGHLIGHTS FDA approved BridgeBio's new heart disease ...

This drug is not approved for any use. In May 2020, researchers in the U.S. and China launched phase-2 clinical trials ... 14403 Eli Lilly and Company: Press Release FDA approves OLUMIANT® ...

Acoramidis is the first FDA-approved treatment for ATTR-CM with near-complete TTR stabilization, reducing cardiovascular death and hospitalization. The phase 3 ATTRibute-CM trial showed acoramidis ...

Nov 22 (Reuters) - (This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3) The oral drug, branded as Attruby, was approved to ...

The first and only anti-tissue factor pathway inhibitor (anti-TFPI) has been approved in the EU for the treatment of haemophilia A and B, with Pfizer’s drug gaining marketing ... the standard-of-care ...

Pfizer PFE announced that the European Commission (“EC”) has granted marketing authorization for Hympavzi (marstacimab) to treat certain hemophilia patients. With this nod, the once-weekly ...

The study achieved its primary endpoint — treatment with the drug ... Pfizer have lost 13.4% against the industry’s 3.1% growth. The latest decision marks the second EC approval for Pfizer this year ...